Dipeptidyl peptidase IV (DPP4) inhibitors are orally available anti-diabetic agents that decrease blood glucose by preventing the degradation of incretions' such as glucagon-like peptide 1 and gastric inhibitory peptide. The global market for DPP4 inhibitors has been forecast to reach $10.1 billion by the year 2017. Diabetics are at increased risk of cardiovascular death. Interruption of the renin-angiotensin system (RAS) reduces cardiovascular risk in patients with diabetes and heart disease. In two recent clinical trials examining the cardiovascular effects of DPP4 inhibitors, over eighty percent of patients were taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Understanding the interactive cardiovascular effects of DPP4 inhibitors and RAS inhibiting drugs is of the utmost importance. In addition to preventing degradation of incretins, DPP4 inhibitors prevent degradation of other peptides with a penultimate amino-terminus arginine or proline, including the ACE substrate substance P. During ACE inhibition, an increased proportion of substance P is degraded by DPP4. Inhibition of both DPP4 and ACE potentiates effects of substance P in rodents. Substance P causes vasodilation and vascular permeability, but also stimulates release of norepinephrine and the DPP4 substrate neuropeptide Y (NPY) from nerve terminals. Sympathetic activation by substance P could have deleterious effects in hypertension and heart failure. We have discovered an interactive effect of DPP4 inhibition on the hemodynamic response to ACE inhibition that may reduce the cardioprotective effect of ACE inhibitors. Specifically we have found that DPP4 inhibition attenuates the antihypertensive response to acute maximal ACE inhibition and increases heart rate and circulating norepinephrine in individuals with the metabolic syndrome. In addition, we have found that intra- arterial substance P stimulates vascular release of norepinephrine when DPP4 and ACE are both inhibited. We propose to test the overarching hypothesis that DPP4 inhibition attenuates the antihypertensive effect of chronic ACE inhibition by increasing activation of the sympathetic nervous system by endogenous substance P.
In Aim 1, we will test the hypothesis that DPP4 inhibition attenuates the anti-hypertensive response to chronic ACE inhibition, but not angiotensin receptor blockade, in patients with type 2 diabetes. We will assess the contribution of endogenous substance P to the effects of combined DPP4 and ACE inhibition using the substance P (NK1) receptor blocker aprepitant.
In Aim 2, we will test the hypothesis that substance P increases norepinephrine spillover and net vascular release of NPY through an NK1 receptor-dependent mechanism during concurrent inhibition of DPP4 and ACE in individuals with type 2 diabetes.
In Aim 3, we will test the hypothesis that DPP4 inhibition also prevents the degradation of NPY, leading to increased vasoconstriction and forearm norepinephrine spillover in diabetics. The results of this proposal could impact on the treatment of millions of patients with type 2 diabetes.
Worldwide 336 million people suffer from diabetes. Many patients with diabetes take drugs called angiotensin- converting enzyme (ACE) inhibitors to reduce their risk of heart disease, stroke and kidney injury. This project investigates the possibility that a widely used new class of diabetes drugs called dipeptidyl peptidase 4 inhibitors reduces the beneficial effects of ACE inhibitors in heart disease and will suggest individualized treatment strategies to reduce the risk of heart disease while controlling blood sugar.
Showing the most recent 10 out of 11 publications
